Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 25 2021 - 4:45PM
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company
developing transformative therapies for the treatment of cancer and
rare diseases, today announced the grants of inducement
non-qualified stock options to purchase an aggregate of 44,000
shares of common stock to Mary Grendell, Protara’s new General
Counsel.
Each stock option has an exercise price per
share equal to $6.81 per share, Protara’s closing trading price on
October 25, 2021, the grant date, and will vest over four years,
with 25% of the underlying shares vesting on the one-year
anniversary of the grant date and 1/36th of the underlying shares
vesting monthly thereafter over 36 months subject to Ms. Grendell’s
continued service relationship with Protara through the applicable
vesting dates.
The Compensation Committee of Protara’s Board of
Directors approved the awards as an inducement material to Ms.
Grendell’s employment in accordance with Nasdaq Listing Rule
5635(c)(4).
About Protara Therapeutics
Protara is committed to identifying and
advancing transformative therapies for people with cancer and rare
diseases with limited treatment options. Protara’s portfolio
includes its lead program, TARA-002, an investigational cell-based
therapy being developed for the treatment of non-muscle invasive
bladder cancer and lymphatic malformations, and IV Choline
Chloride, an investigational phospholipid substrate replacement
therapy for the treatment of intestinal failure-associated liver
disease. For more information, visit www.protaratx.com
Company Contact:
Justine O'MalleyProtara
TherapeuticsJustine.OMalley@protaratx.com646-817-2836
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jul 2023 to Jul 2024